{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T07:29:44Z","timestamp":1744270184293,"version":"3.37.3"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":646,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1093\/annonc\/mdy084","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T11:32:54Z","timestamp":1521199974000},"page":"796-798","source":"Crossref","is-referenced-by-count":1,"title":["Taking it in the chin: vitamin K1 for the prevention of acneiform rash"],"prefix":"10.1016","volume":"29","author":[{"given":"M.E.","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1093\/annonc\/mdy084_bb0010","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/annonc\/mdy015","article-title":"EVITA\u2014a double-blind, vehicle controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity","volume":"29","author":"Hofheinz","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdy084_bb0015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"10.1093\/annonc\/mdy084_bb0020","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy084_bb0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"3-4","key":"10.1093\/annonc\/mdy084_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"issue":"22","key":"10.1093\/annonc\/mdy084_bb0035","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Per\u00e9z-Soler","year":"2005","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1093\/annonc\/mdy084_bb0040","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy084_bb0045","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy084_bb0050","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.2015.62.3918","article-title":"Pan Canadian Rash Trial: a Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer","volume":"34","author":"Melosky","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy084_bb0055","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jaad.2017.03.039","article-title":"A prospective, randomized, double-blinded, split-face\/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash","volume":"77","author":"Belum","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1093\/annonc\/mdy084_bb0060","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdw227","article-title":"A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer","volume":"27","author":"Lacouture","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy084_bb0065","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.febslet.2006.02.048","article-title":"Activation of ErbB2 by 2-methyl-1, 4-naphthoquinone (menadione) in human keratinocytes: role of EGFR and protein tyrosine phosphatases","volume":"580","author":"Beier","year":"2006","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1093\/annonc\/mdy084_bb0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clcc.2013.10.001","article-title":"Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer","volume":"13","author":"Pinta","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdy084_bb0075","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1600-0625.2008.00715.x","article-title":"A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition","volume":"17","author":"Wollenberg","year":"2008","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1093\/annonc\/mdy084_bb0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jnci\/djm324","article-title":"Is there room for improvement in adverse event reporting in the era of targeted therapies?","volume":"100","author":"Edgerly","year":"2008","journal-title":"J Natl Cancer Inst"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419454999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419454999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/4\/796\/25082611\/mdy084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:44:28Z","timestamp":1624700668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419454999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0923753419454999"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy084","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}